Finite depletion, sustained control: can impulse therapy prevent rebound activity in multiple sclerosis?
Marc Pawlitzki, Lars Masanneck, Antonio Scalfari, Gavin Giovannoni · 2026
Read Finite depletion, sustained control: can impulse therapy prevent rebound activity in multiple sclerosis? by Marc Pawlitzki, Lars Masanneck, Antonio Scalfari, Gavin Giovannoni (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13638323.txt.
Description
Pawlitzki, Masanneck, Scalfari, and Giovannoni comment on fresh evidence about stopping a strong immune drug in multiple sclerosis. The drug clears a type of white blood cell that drives attacks on the nerves. Long use, though, can lower protective proteins and raise the chance of infections.
A recent study found that stable patients who stopped the drug after about 30 months saw no clear rise in disease activity. Follow-up lasted a median of just over two years. The writers urge care in reading that result, since the margins of error were wide. Activity did creep up after two years off the drug. They frame the next question as how to step treatment down safely, under close watch, rather than whether stopping is simply safe.
Catalog record
| CREATOR | Marc Pawlitzki, Lars Masanneck, Antonio Scalfari, Gavin Giovannoni |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |